
GLP-1 Receptor Agonist Analog
MISSION CRITICAL: For in vitro laboratory research only. Not for human or veterinary use. Not evaluated by the FDA. Must be 21+.
GLP-1(S) is a semaglutide-class GLP-1 receptor agonist research peptide with the molecular formula C₁₈₇H₂₉₁N₄₅O₅₉ and a molecular weight of 4113.58 g/mol (CAS: 910463-68-2), characterized by a C18 fatty diacid side chain enabling albumin binding and extended plasma half-life in preclinical pharmacokinetic studies. Supplied at ≥99% HPLC purity as a lyophilized powder, GLP-1(S) is designated for in vitro research on GLP-1 receptor signaling pathways only.
GLP-1(S) binds GLP-1R and activates adenylyl cyclase, elevating intracellular cAMP in pancreatic and intestinal cell models (PMID: 28890133).
The C18 fatty diacid side chain enables non-covalent albumin binding, extending pharmacokinetic half-life in plasma protein binding assays (PMID: 29393665).
Lau et al. (2017) characterized GLP-1 analog receptor binding affinity and albumin-binding pharmacokinetics in in vitro models (PMID: 28890133).
Lau J, et al. (2017). Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem.PMID: 29393665Nauck et al. (2018) examined GLP-1R agonist signal transduction and downstream cAMP generation in pancreatic beta-cell culture (PMID: 29393665).
Nauck MA, et al. (2018). Incretin therapies: mechanisms of action, metabolism and safety. Diabetes Obes Metab.Scientific Context